EMA Authorised: Kinzalkomb (telmisartan;hydrochlorothiazide) — Bayer AG

View source ↗

Summary

Kinzalkomb, a fixed-dose combination of telmisartan and hydrochlorothiazide, has been authorised by the EMA for the treatment of hypertension. The marketing aut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Kinzalkomb (telmisartan and hydrochlorothiazide)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Bayer AG. Decision date: 07/01/2025